Jump to main content
Jump to site search

Issue 1, 2019
Previous Article Next Article

Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma

Author affiliations

Abstract

Multiple myeloma, an incurable malignancy of the plasma cells in the bone marrow, has a complex pathogenesis due to clonal heterogeneity. Over the years, many clinical trials and researches have led to the development of effective myeloma treatments, resulting in survival prolongation. Molecular prognostic markers for risk-stratification to predict survival, and predictive markers for treatment response are being extensively explored. This review discusses the current risk-adaptive strategies based on genetic and molecular risk signatures that are in practice to predict survival and describes the future prognostic and predictive biomarkers across the fields of genomics, proteomics, and glycomics in myeloma. Gene expression profiling and next generation sequencing are coming to the forefront of risk-stratification and therapeutic-response prediction. Similarly, proteomic and glycomic-based platforms are gaining momentum in biomarker discovery to predict drug resistance and disease progression.

Graphical abstract: Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma

Back to tab navigation

Publication details

The article was received on 16 Aug 2018, accepted on 20 Dec 2018 and first published on 07 Jan 2019


Article type: Review Article
DOI: 10.1039/C8MO00193F
Mol. Omics, 2019,15, 7-20

  •   Request permissions

    Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma

    G. N. Lê, J. Bones, M. Coyne, D. Bazou, P. Dowling, P. O’Gorman and A. Larkin, Mol. Omics, 2019, 15, 7
    DOI: 10.1039/C8MO00193F

Search articles by author

Spotlight

Advertisements